Calcium channel inhibition accelerates polycystic kidney disease progression in the Cy/+ rat  by Nagao, S. et al.
see commentary on page 251
Calcium channel inhibition accelerates polycystic
kidney disease progression in the Cy/þ rat
S Nagao1,2,6, K Nishii1,6, D Yoshihara1,2, H Kurahashi3, K Nagaoka3,4, T Yamashita5, H Takahashi1,
T Yamaguchi2,5, JP Calvet2 and DP Wallace2
1Education and Research Center of Animal Models for Human Diseases, Fujita Health University, Toyoake, Aichi, Japan; 2Department of
Medicine, The Kidney Institute, University of Kansas Medical Center, Kansas City, Kansas, USA; 3Division of Molecular Genetics, Fujita
Health University, Toyoake, Aichi, Japan; 4Development Center for Targeted and Minimally Invasive Diagnosis and Treatment, Fujita
Health University, Toyoake, Aichi, Japan and 5Tsuminori Institute of Preventative Medicine, Kagoshima, Japan
In polycystic kidney disease, abnormal epithelial cell
proliferation is the main factor leading to cyst formation and
kidney enlargement. Cyclic AMP (cAMP) is mitogenic in cystic
but antimitogenic in normal human kidney cells, which is due
to reduced steady-state intracellular calcium levels in cystic
compared to the normal cells. Inhibition of intracellular
calcium entry with channel blockers, such as verapamil,
induced cAMP-dependent cell proliferation in normal renal
cells. To determine if calcium channel blockers have a similar
effect on cell proliferation in vivo, Cy/þ rats, a model of
dominant polycystic kidney disease, were treated with
verapamil. Kidney weight and cyst index were elevated in
verapamil-treated Cy/þ rats. This was associated with
increased cell proliferation and apoptosis, elevated
expression, and phosphorylation of B-Raf with stimulation
of the mitogen-activated protein kinase MEK/ERK
(mitogen-activated protein kinase kinase/extracellular-regulated
kinase) pathway. Verapamil had no effect on kidney
morphology or B-Raf stimulation in wild-type rats. We
conclude that treatment of Cy/þ rats with calcium channel
blockers increases activity of the B-Raf/MEK/ERK pathway
accelerating cyst growth in the presence of endogenous
cAMP, thus exacerbating renal cystic disease.
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Autosomal-dominant polycystic kidney disease (ADPKD) is a
common hereditary renal disorder caused by mutations in
PKD1 or PKD2.1–6 Aberrant growth of renal epithelial cells
leads to the formation of fluid-filled cysts that destroy
surrounding tissue and disrupt renal function. Polycystin-1
(PC-1) and polycystin-2 (PC-2), the products of PKD1 and
PKD2, respectively, are multifunctional proteins implicated
in the regulation of cell proliferation via multiple signaling
pathways. PC-1 and PC-2 form a Ca2þ -permeable cation
channel7–9 and colocalize to primary cilia of cells.10,11 It
remains unclear how functional loss of PC-1 or PC-2 disrupts
intracellular Ca2þ regulation and gives rise to an abnormal
cell proliferation phenotype. Recent evidence has shown that
epithelial cells isolated from human ADPKD cysts have an
aberrant intracellular Ca2þ response to ciliary sensing of
fluid flow12 and reduced intracellular Ca2þ levels compared
to normal renal cells.13 Thus, renal cell hyperplasia in
ADPKD may be a result of dysfunctional intracellular Ca2þ
metabolism.
Cyclic AMP (cAMP) agonists, including arginine vaso-
pressin, accelerate the proliferation of cyst-derived cells
through activation protein kinase A and subsequent stimula-
tion of the B-Raf/mitogen-activated protein kinase kinase/
extracellular regulated kinase (MEK/ERK) pathway.13–19 By
contrast, cAMP does not activate ERK or proliferation of
normal renal cells. This phenotypic difference in the
proliferative response to cAMP appears to be secondary to
differences in basal intracellular Ca2þ levels. Sustained
reduction of intracellular Ca2þ with Ca2þ channel blockers
(CCBs), including verapamil and nifedipine (L-type CCBs),
predisposed cells cultured from normal human kidneys to
cAMP-dependent activation of the B-Raf/MEK/ERK pathway
and increased cell proliferation, mimicking the ADPKD cell
phenotype.15 Treatment of ADPKD cells with Ca2þ entry
blockers amplified cAMP-dependent ERK activation and
proliferation, suggesting that further reduction in intra-
cellular Ca2þ may accelerate cyst growth.13
To investigate the effect of CCBs on growth of renal
cysts, verapamil was administered twice daily for 7 weeks
to Han:SPRD Cy/þ rats. This classical rodent model of
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polycystic kidney disease (PKD) transmits the disease in an
autosomal-dominant pattern and thus resembles human
ADPKD.20 This model has been used to investigate factors
that modulate the progression of renal cystic disease.21
Previously, Cowley et al.22 showed that cyst progression could
be accelerated by growth-promoting stimuli, including
NH4Cl, K
þ restriction, and increased dietary protein.
An advantage of this model is the sexual dimorphism in
the progression of Cy/þ renal disease. Male rats have a
more rapid disease progression, whereas the disease in
females is relatively mild. Thus, drug treatment can be
investigated in mild and severe forms of PKD using the same
animal model.
In this study, we determined if verapamil, a CCB that
reduces Ca2þ in cultured renal cells, enhances cell prolifera-
tion and cyst enlargement in Cy/þ rats. Cy/þ and þ /þ
female and male rats were treated with verapamil from age 5
to 12 weeks, and renal morphology, cellular proliferation and
apoptosis, and renal activity of the B-Raf/MEK/ERK pathway
were determined.
RESULTS
Effect of verapamil on kidney weight, SUN, and renal cystic
index
Blood pressure (BP) of 12-week-old Cy/þ rats was
significantly higher than that of þ /þ rats (17476 vs
15274 mm Hg, Po0.001) (Figure 1). Treatment with
20 mg kg1 verapamil twice daily decreased BP of the
Cy/þ rats to 14279 mm Hg (Po0.001, compared to
control-treated Cy/þ rats). This demonstrates that
verapamil dosing with this concentration was sufficient to
normalize BP in Cy/þ rats without inducing hypotension in
þ /þ animals (14473 mm Hg).
At 12 weeks, serum urea nitrogen (SUN) was relatively
normal in control-treated female Cy/þ rats compared to
control-treated þ /þ rats (Figure 2). Verapamil treatment
for 7 weeks increased SUN in female Cy/þ rats from
32.471.8 to 42.673.8 mg per 100 ml (Po0.01). This effect
of verapamil on SUN was less pronounced in male Cy/þ rats
on a percentage basis, which already have elevated SUN levels
above 80 mg per 100 ml, indicating an advanced stage of renal
insufficiency at 12 weeks. As such, SUN levels were higher in
Cy/þ males following verapamil treatment (83.675.6 mg
per 100 ml for the control-treated vs 98.178.2 mg per 100 ml
for verapamil-treated male rats). Verapamil had no effect on
SUN levels in male or female þ /þ rats.
Body weight of sex-matched Cy/þ and þ /þ littermates
did not differ and was unaffected by verapamil treatment
(Figure 3). By contrast, kidney weight (% body weight) was
2- and 2.9-fold greater in the Cy/þ female and male rats,
respectively, compared to þ /þ rats. Verapamil increased
kidney weight 35% in the Cy/þ females and 50% in Cy/þ
males compared to control-treated Cy/þ rats. Measurement
of the cystic area in representative histological kidney sections
revealed that verapamil increased cystic surface area from
13.071.0 to 31.770.7% of total area (Po0.001) in female
kidneys and from 29.771.9 to 52.073.5% (Po0.001) in Cy/
þ male kidneys (Figure 4). Importantly, verapamil treat-
ment failed to induce renal cyst formation in normal rats
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Figure 1 | Effect of verapamil (VP) on systolic BP in Cy/þ and
normal þ /þ rats. Verapamil (20 mg kg1) or control solution
(CONT) was given by oral gavage every 12 h from age 5 to 12 weeks.
Systolic BP was measured at 11.5 weeks by the tail-cuff method.
Systolic BP of Cy/þ rats was significantly elevated compared
to þ /þ rats (*Po0.01). Verapamil treatment normalized systolic BP
in Cy/þ rats. Comparison between VP vs CONT-treated Cy/þ rats
(male and female), #Po0.001. There was no effect of VP on the
BP of þ /þ rats.
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Figure 2 | Effect of verapamil (VP) on serum urea nitrogen (SUN)
in Cy/þ and normal þ /þ rats. At 12 weeks, control-treated
(CONT) female Cy/þ rats (n¼ 9) had normal SUN levels compared to
CONT female þ /þ rats (n¼ 7), consistent with a relatively mild
stage of renal disease. By contrast, CONT male Cy/þ rats (n¼ 5) had
SUN values 3.3-fold higher than that in CONT male þ /þ rats (n¼ 9),
indicating advanced stage of renal disease (*Po0.001). Treatment
with VP caused a significant increase in SUN in female Cy/þ animals
(n¼ 5), **Po0.01. SUN levels in VP-treated Cy/þ males (n¼ 8) were
not statistically different from CONT-treated Cy/þ males (P¼ 0.09).
The changes in SUN with verapamil treatment in Cy/þ males
(D¼ 14.5 mg per 100 ml) were similar (if not greater) than in
Cy/þ females (D¼ 10.24 mg per 100 ml), indicating that verapamil had
an impact on SUN levels in both female and male Cy/þ rats. VP had no
effect on SUN levels in þ /þ female (n¼ 10) or male (n¼ 7) rats.
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(data not shown) and had no effect on kidney weight
(Figure 3).
Effect of verapamil on cell proliferation and activity of the
B-Raf/MEK/ERK pathway in Cy/þ kidneys
Intracellular cAMP is a central mitogenic factor for the
progression of renal disease. We found that urinary cAMP
levels were fourfold higher in the Cy/þ male rats than in
normal rats (1540 vs 6289 pmol per 24 h, n¼ 2 per group),
suggesting that renal cAMP production was elevated in
Cy/þ kidneys consistent with several other rodent models
of PKD.17,18,23 Immunohistochemical analysis revealed
that control-treated Cy/þ kidneys had significantly higher
levels of proliferating cell nuclear antigen (PCNA)-positive
cells than control-treated þ /þ kidneys (Figure 5). Verapa-
mil increased the number of PCNA-positive cells in female
Cy/þ kidneys from 20.674.2 to 39.371.2% (Po0.01) and
in male Cy/þ kidneys from 24.371.3 to 30.071.0%
(Po0.001). By contrast, there were few PCNA-positive cells
in þ /þ kidneys and verapamil had no effect on the number
of proliferating cells. In female Cy/þ rats, verapamil
treatment increased the number of PCNA-positive epithelial
cells in normal and dilated renal tubules, and cysts compared
to control-treated animals (Table 1). A similar trend was
observed in the male Cy/þ kidneys. Verapamil treatment
had no effect on the proliferation of interstitial cells.
Previously, we found that ERK activity generally reflected
the mass of cystic epithelia within Cy/þ kidneys.24 To
determine if verapamil treatment increased the activity of the
B-Raf/MEK/ERK pathway, we measured levels of B-Raf, ERK,
and phosphorylated form of B-Raf (P-BRaf) and ERK
(P-ERK) in normal and cystic kidneys by immunoblot
analysis (Figure 6, Table 2). There was no consistent
difference between normal and Cy/þ female kidneys in the
expression of the 95 kDa isoform of B-Raf and ERK; and the
level of P-ERK was only slightly increased in female Cy/þ
kidneys consistent with the mild cystic phenotype.24 Treat-
ment with verapamil increased the expression of B-Raf and
increased the levels of P-BRaf/B-Raf and P-ERK/ERK in Cy/
þ female kidneys. By contrast, renal B-Raf expression and
the activity of the B-Raf/MEK/ERK pathway were already
elevated in male Cy/þ rats. There were higher levels of
P-BRaf and P-ERK in the male Cy/þ kidneys treated with
verapamil; however, a statistically significant effect of
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Figure 3 | Effect of verapamil (VP) treatment on kidney weight in
Cy/þ and normal rats. Female and male Cy/þ and þ /þ rats were
treated with VP or control solution by twice daily oral dosing.
At 12 weeks of age, total body weight was measured and kidneys
were collected to determine total kidney weight, represented as
a percentage of body weight (%BW). (a) Cy/þ female and male
rats had larger kidneys than þ /þ littermates (*Po0.001).
Verapamil treatment caused a significant increase in kidney weight
in both genders of Cy/þ rats (**Po0.001), but had no effect on
total kidney weight of þ /þ rats. (b) Total body weight did not differ
between sex-matched Cy/þ and þ /þ rats and was unaffected
by verapamil treatment. Statistical differences between VP and
control (CONT)-treated rats (either Cy/þ or þ /þ ) were determined
by one-way analysis of variance.
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Figure 4 | Effect of verapamil (VP) on renal cyst development
in female and male Cy/þ rats. Representative kidney sections
obtained from (a) female or (b) male Cy/þ rats treated with either
CONT or VP. (c) Cross-sectional surface area of cysts, represented
as % of total area (mean7s.e.), from representative sections of
Cy/þ kidneys was measured by morphometric analysis. Comparisons
between CONT and VP showed that VP increased cyst area 140%
in the female kidneys and 75% in Cy/þ male kidneys, *Po0.001.
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verapamil on P-BRaf and P-ERK could not be demonstrated
because of the already elevated levels. By contrast, verapamil
treatment had no effect on B-Raf, ERK, P-BRaf, or P-ERK
levels in þ /þ kidneys. We propose that renal cystic disease
is related to the activity of the B-Raf/MEK/ERK pathway in
the Cy/þ rats, and CCB increases the activity of B-Raf/MEK/
ERK pathway and PKD severity. This effect of verapamil was
best demonstrated in female Cy/þ rats, which have a milder
disease phenotype. Male Cy/þ kidneys already have elevated
B-Raf expression and ERK activity and advanced renal cystic
disease.
Cellular hyperplasia and apoptosis are both hallmarks of
hereditary cystic kidney diseases. To determine if verapamil
treatment altered the number of apoptotic cells, we used a
TdT-mediated dUTP nick end labeling assay to count the
number of apoptotic cells in Cy/þ rats treated with either
verapamil or vehicle control. Consistent with previous
reports,27 the number of apoptotic cells (% of total cells
counted per field) in the kidneys of Cy/þ rats was
significantly higher than in þ /þ kidneys (Table 3).
Verapamil treatment increased the % apoptotic cells in Cy/þ
female and male kidneys 70 and 87%, respectively. Apoptotic
cells in dilated tubules and cysts were significantly increased
in verapamil-treated Cy/þ rats. By contrast, apoptotic levels
were unaffected in normal tubule cells or interstitial cells.
DISCUSSION
Intracellular Ca2þ signaling in epithelial cells is important
for regulation of a variety of cellular functions, including cell
volume regulation, ion and fluid transport, differentiation
and cell proliferation.28 Various types of Ca2þ channels have
been identified in renal tubule cells, including non-selective
cation channels,29,30 store-operated Ca2þ channels,31 and
voltage-activated Ca2þ channels.32 There are at least four
types of voltage-dependent Ca2þ channels (L, N, T, and P) in
excitable cells that can be distinguished on the basis of
electrophysiological and pharmacological properties. Several
studies have demonstrated that L-type Ca2þ channels are
also present in non-excitable tissues.33,34 Ca2þ channels have
been identified in renal tubule cells, which are sensitive to the
dihydropyridine Ca2þ channel blocker nifedipine and the
activator Bay-K8644,35,36 characteristics of L-type Ca2þ
channels. L-type Ca2þ channels are composed of multiple
subunits (a1, a2, b, g, and d) with the a1-subunit comprising
the channel core, voltage sensor, and drug-binding sites for
dihydropyridine, phenylalkylamines (that is, verapamil), and
benzothiazepines (that is, diltiazem).37,38 The a1c-subunit
of the cardiac L-type Ca2þ channel localizes to both the
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Figure 5 | Effect of verapamil (VP) treatment on cell proliferation
in Cy/þ and þ /þ kidneys. Representative kidney sections from
(a) CONT-treated Cy/þ female, (b) VP-treated Cy/þ female,
(c) CONT-treated Cy/þ male, and (d) VP-treated Cy/þ male rats
stained with an antibody to proliferating cell nuclear antigen (PCNA),
a proliferation marker. All images are at the same magnification.
(e) The number of PCNA-positive cells is represented as % of total
cells in the kidney section. Approximately 20–25%‘ of the cells in the
Cy/þ kidneys (female and male) stained positive for PCNA. VP
treatment increased the PCNA-positive cells in the Cy/þ kidneys.
Comparison between VP vs CONT-treated Cy/þ rats (female or
male), *Po0.01. By contrast, there were few PCNA-positive cells in
þ /þ kidney sections and VP had no effect on the proliferative index
(representative sections of þ /þ kidneys not shown).
Table 1 | Effect of VP on PCNA-positive cells in Cy/+ kidneys
Epithelial cells
Treatment N
Normal
tubules
Dilated
tubules Cysts
Interstitial
cells
Female Cy/+
CONT 3 7.870.8 8.971.1 9.172.7 18.275.4
VP 3 13.771.7* 16.272.0* 21.671.5* 14.073.4
Male Cy/+
CONT 3 14.270.6 15.973.6 17.370.2 16.174.5
VP 3 20.274.8 23.872.7 23.672.0* 10.372.3
CONT, control; PCNA, proliferating cell nuclear antigen; VP, verapamil.
Summary of the effect of VP treatment on PCNA-positive epithelial cells of normal
tubules (diameter p50 mm), dilated tubules (50 mmodiameterp100 mm), and cysts
(diameter4100 mm); and interstitial cells in Cy/+ male and female kidneys. The data
are % PCNA-positive cells (mean7s.e.) counted from 900 to 1400 cells per thin
section of cortex. VP (20 mg kg1 given twice daily) caused a significant increase in
PCNA-positive cells in normal and dilated tubules, and cysts within the female Cy/+
kidneys (*Po0.05). In male Cy/+ kidneys, a significant increase in PCNA-positive cells
was demonstrated only in the cysts (*Po0.05); however, the number of cells in
normal and dilated tubules that stained positive for PCNA was greater in VP-treated
compared to CONT-treated kidneys. There was no effect of VP on interstitial cells in
female or male Cy/+ kidneys. A comparison of the effect of VP treatment on PCNA-
positive epithelial cells (tubules and cysts) of male and female Cy/+ and +/+ kidneys
is shown in Figure 5.
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basolateral and apical membranes of rat medullary collecting
ducts, and the mRNA for the a1c-subunit has been
demonstrated in rat proximal tubules, and cortical and
medullary collecting ducts.39 Moreover, Ca2þ channels with
characteristics of L-type Ca2þ channels have been identified
in apical membranes of rabbit proximal tubules, cortical
thick ascending limbs, distal convoluted tubules, and cortical
collecting ducts.35,40,41 Taken together, these localization
studies suggest a broad distribution of L-type Ca2þ channels
throughout the nephron and collecting duct.
Epithelial Ca2þ channels share structural similarities to
channels found in excitable cells, but may have different
channel properties. Currently, it is unclear if these epithelial
Ca2þ channels are the same voltage-gated channels expressed
in excitable tissue. Zhang and O’Neil42 cloned a Ca2þ
channel cDNA from renal epithelial cells that had a sequence
identical to the a1c-subunit, except for a 11 amino-acid
deletion, indicating a splice variant of the cardiac Ca2þ
channel. In excitable cells, L-type channels can be distin-
guished from other voltage-gated channels by activation at
relatively large membrane depolarization and by slow channel
inactivation. In contrast, Ca2þ entry in distal convoluted
tubule cells was found to be accompanied by membrane
hyperpolarization.43 Thus, Ca2þ signaling in renal epithelial
cells may be mediated by unique Ca2þ channels that
are distinct from the classical L-type Ca2þ channels.
Nevertheless, pharmacological properties of these renal
Ca2þ channels may be similar to L-type Ca2þ channels in
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Figure 6 | Effect of verapamil (VP) treatment on the renal activity of the B-Raf/MEK/ERK pathway in Cy/þ and þ /þ kidneys.
Immunoblot analysis was used to compare expression levels of total B-Raf and ERK, and phosphorylated levels of B-Raf (P-BRaf) and ERK
(P-ERK) in kidneys from Cy/þ and þ /þ (female and male) rats. In the female Cy/þ kidneys, P-BRaf and P-ERK were slightly elevated
above þ /þ kidneys, and treatment with VP increased both P-BRaf and P-ERK. B-Raf, ERK, P-BRaf, and P-ERK were elevated in male
Cy/þ kidneys compared to þ /þ kidneys, and VP treatment did not cause an appreciable increase in these levels. There was no effect of
VP on B-Raf and ERK activity in the þ /þ kidneys. Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) was used as a loading control.
A summary of the effects of verapamil on the expression of B-Raf, ERK, and levels of P-BRaf and P-ERK is presented in Table 2.
Table 2 | Effect of VP on the activity of the B-Raf/MEK/ERK pathway in Cy/+ and +/+ kidneys
Genotype Treatment N P-BRaf/B-Raf B-Raf P-ERK/ERK ERK
Female
+/+ CONT 5 1.0070.00 1.0070.00 1.0070.00 1.0070.00
+/+ VP 5 1.1570.11 0.7670.17 1.0470.08 0.9870.11
Cy/+ CONT 5 1.8170.07z 1.1670.05 2.0770.21 1.1670.10
Cy/+ VP 5 2.1670.17z,** 1.4170.11* 3.7570.63z,# 1.0370.05
Male
+/+ CONT 5 1.0070.00 1.0070.00 1.0070.00 1.0070.00
+/+ VP 5 1.0070.08 0.9470.03 1.6270.50 0.9870.08
Cy/+ CONT 5 1.8870.23w 1.6570.24* 4.7770.58w 1.1370.14
Cy/+ VP 5 1.9670.27w 1.8670.27* 6.5070.98z 1.0970.12
CONT, control; ERK, extracellular-regulated kinase; MEK, mitogen-activated protein kinase kinase; VP, verapamil.
Summary of the effect of VP treatment on renal expression and activity of B-Raf (95 kDa isoform), and ERK in normal (+/+) and Cy/+ female and male rats. Expression levels for
ERK and B-Raf were normalized to glyceraldehyde-3-phosphate dehydrogenase, a loading control. Antibodies were used to detect the phosphorylation of S446 of B-Raf
(P-BRaf) and Y204 of ERK (P-ERK) and relative activity levels were expressed as P-BRaf/B-Raf and P-ERK/ERK, respectively. It has been reported that S446 (previously S445) of B-Raf
is constitutively phosphorylated in proliferating cells and tumor cell lines.25 However, it has been shown recently that phosphorylation at this site is negatively regulated
by Rheb, and that S446 phosphorylation promotes binding of B-Raf to H-Ras.26 Comparison to +/+ kidneys (*Po0.05, wPo0.01, zPo0.001); comparison between CONT and
VP treatment in either Cy/+ or +/+ kidneys (**Po0.05, #Po0.01).
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that they are sensitive to the three classes of CCBs
(nifedipine, verapamil, and diltiazem).
Polycystins are multifunctional proteins that appear to be
involved in Ca2þ signaling in renal epithelial cells and may
transmit environmental signals into a cellular response that
regulates cell differentiation and proliferation. PC-2 is a
member of the family of transient receptor potential
channels.4,44,45 PC-1 interacts with PC-2 through a coiled-
coil domain and may regulate PC-2 channel activity within
the plasma membrane. Recent evidence suggests that
functional loss of the polycystins leads to disruption of
flow-mediated Ca2þ signaling3 and lower basal Ca2þ levels
in cystic cells compared to non-cystic cells.13 Aberrant
intracellular Ca2þ signaling in renal epithelial cells allows
cAMP activation of the MEK/ERK pathway and increased cell
proliferation,15 an important factor in the enlargement of
renal cysts.13–15,18,19,46–48 This phenotypic difference in the
cAMP mitogenic response between normal renal cells and
PKD cells is linked to cAMP-dependent B-Raf signaling to
the MEK/ERK pathway. Normally, B-Raf is repressed by Akt
(protein kinase B), which is downstream of the phosphati-
dylinositol 3-kinase pathway.15 This mitogenic response to
cAMP could be induced experimentally in normal renal cells
by reducing intracellular Ca2þ with L-type CCBs, verapamil
and nifedipine, and the non-selective cation channel blocker
gadolinium. Restriction of intracellular Ca2þ decreased Akt
activity allowing cAMP-dependent activation of B-Raf and
cell proliferation, thus mimicking ADPKD cells.15 Basal
activity of Akt is diminished in human ADPKD cells
compared to normal renal cells. CCB treatment of ADPKD
cells, which already have a reduced Ca2þ level, caused a
further reduction in Akt activity and amplified the cAMP-
dependent ERK activation and cell proliferation.13 These
findings led us to hypothesize that CCB treatment in animals
with PKD may have an adverse effect on disease progression
by amplifying the activity of the B-Raf/MEK/ERK
pathway and, thereby, increasing the proliferation rate of
cyst-lining cells.
In the Cy/þ model of dominantly inherited cystic disease,
kidneys enlarge owing to aberrant proliferation of tubule
epithelial cells mediated by ERK activation.24 We found that
urinary cAMP levels were increased in Cy/þ rats compared
to þ /þ rats, consistent with an elevation of intracellular
cAMP in the kidneys in several rodent models of PKD.17,18
This increased production of cAMP, either basal or
stimulated by activation by G-protein-coupled receptors,
could account for this elevation in ERK activity. Cysts
develop primarily in the proximal tubule in this model due to
mutations in samcystin, which has an undefined function.49
The reliable progression of kidney disease makes this a
particularly useful model for identifying factors that alter
disease severity.50,51
Treatment of Cy/þ rats with verapamil for 7 weeks
returned BP to a normal level (Figure 1). However, this
sustained treatment with a CCB caused a significant increase
in total kidney weight (Figure 3) and in the size of cysts
(Figure 4). Moreover, Cy/þ females, which have a mild
disease phenotype at 12 weeks, had significantly increased
SUN following CCB treatment, reflecting an adverse effect on
renal function. The increase in cystic area was associated with
increased proliferation of tubule and cystic epithelial cells
(Figure 5 and Table 1) and elevated apoptosis of cells in
dilated tubules and cysts (Table 3). Examination of signaling
intermediates revealed that verapamil treatment increased the
level of B-Raf and the activity of the MEK/ERK pathway
(Figure 6 and Table 1). Thus, verapamil treatment,
presumably through inhibition of Ca2þ entry, increased
renal activity of the B-Raf/MEK/ERK pathway and stimulated
the proliferation of the epithelial cells, causing acceleration in
PKD progression that was significant in the female Cy/þ
rats. The effect of verapamil in male Cy/þ kidneys was even
more pronounced, but because of the already elevated
activity of this pathway, did not show a statistically significant
increase. The results also demonstrated that verapamil did
not induce cyst formation in normal kidneys. Previously, we
showed that restriction of intracellular Ca2þ induced a
phenotypic switch in the cAMP proliferative response in
cultured renal cells. As we suggested previously,15 it is
possible that altered gene expression may be required for the
cAMP-dependent proliferative phenotype induced by intra-
cellular Ca2þ restriction.
Potential clinical relevance
CCBs are widely used for treatment of hypertension
associated with chronic kidney diseases, including PKD.
The three chemical types of L-type CCBs (phenylalkylamine,
benzothiazepines, and dihydropyridines) are generally be-
lieved to have similar actions. However, these compounds
have clear differences in their chemical structures, binding
sites, tissue selectivity, and clinical activity.52
Table 3 | Effect of VP on apoptosis in Cy/+ and +/+ kidneys
Genotype Treatment N Apoptotic index (%)
Female
+/+ CONT 3 0.470.2
+/+ VP 3 0.070.0
Cy/+ CONT 3 4.070.8*
Cy/+ VP 3 6.871.2w
Male
+/+ CONT 3 0.671.3
+/+ VP 3 0.670.3
Cy/+ CONT 3 3.870.2*
Cy/+ VP 3 7.170.2**
VP, verapamil.
The number of apoptotic cells was counted from approximately 700 cells per section
of Cy/+ or +/+ kidneys. Apoptotic cells were detected by the ApopTag Peroxidase
In situ Apoptosis Detection Kit (Chemicon International). Female and male Cy/+
kidneys had elevated levels of apoptosis (*Po0.05) compared to +/+ rats. Treatment
with VP increased the number of apoptotic cells in the Cy/+ female (wPo0.05) and
male (**Po0.01) kidneys, but did not affect the level of apoptosis in +/+ rat kidneys.
Apoptotic cells were increased in dilated tubules plus cysts of VP-treated Cy/+
female (2.670.4 vs 7.270.9, Po0.02) and male (3.470.4 vs 8.271.1, Po0.02)
kidneys, whereas normal tubule cells and interstitial cells were unaffected by VP
treatment.
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This study suggests that CCBs can have an adverse effect
on renal disease in PKD; however, additional studies will be
necessary to determine if other L-type CCBs, such as
nifedipine and diltiazem, have similar effects as verapamil,
and if CCBs have adverse effects on PKD progression in other
animal models. Angiotensin-converting enzyme inhibitors,
angiotensin II receptor blockers, and CCBs have similar
beneficial effects on BP control;53 however, there is no
consensus on the type of antihypertensive therapy most
appropriate for PKD patients. In a preliminary report,
Nutahara et al.54 compared the renal-protective effects of
amlodipine, a dihydropyridine L-type CCB, and candesartan,
an angiotensin II receptor blocker, in 49 ADPKD patients
with serum creatinine p2 mg per 100 ml who were treated
for 3 years for hypertension. Patients receiving candesartan
(2–8 mg day1) had less urinary protein and albumin
excretion, better renal function, and a greater renal event-
free survival rate than patients receiving CCB. The authors
concluded that angiotensin II receptor blockers may be
more effective than CCBs for renal protection in patients
with ADPKD, independent of the capacity to control of
hypertension.
In conclusion, treatment with verapamil, a classical
phenylalkylamine L-type CCB, increased the renal activity
of the B-Raf/MEK/ERK pathway and caused acceleration in
growth of renal cysts in Cy/þ rats. Elevation in epithelial cell
proliferation in conjunction with increased apoptosis sug-
gests that a reduction in intracellular Ca2þ levels with CCB
treatment increases the growth and turnover of cyst-lining
epithelial cells, leading to accelerated enlargement of cysts
and kidneys in this rodent model of PKD. The relevance of
these findings to other CCBs and the impact of these agents
in the treatment of PKD remain to be determined.
MATERIALS AND METHODS
Han:SPRD Cy rat model
Han:SPRD Cy rats were originally derived from a strain of
Sprague–Dawley rats in Hanover (Germany),55 and descendants of
this colony have been maintained at Fujita Health University. Male
and female heterozygote (Cy/þ ) rats produced litters containing
Cy/þ , Cy/Cy, and þ /þ littermates. Rats were allowed free access
to water and food throughout the study. Cy/Cy rats die around
3 weeks of age.
There is early onset of renal cyst development in both male and
female Cy/þ rats, but by 8 weeks, there is an obvious difference in
the severity of the disease. Male Cy/þ rats have a more rapid disease
progression and earlier loss of renal function compared to female
Cy/þ rats. Male Cy/þ rats often die of uremia at approximately
1 year, whereas female rats often live to 2 years of age before
significant loss of renal function. This sexual dimorphism in the
progression of cystic disease is related, in part, to the renal androgen
receptor pathway.24 In this study, we examined the effect of a Ca2þ
entry blocker on mild and rapid disease progression by treating
female and male Cy/þ rats with verapamil.
At 5 weeks of age, female and male Cy/þ and þ /þ rats were
randomly assigned to one of the two groups: treatment with
20 mg kg1 verapamil (VP; Sigma Chemical, St Louis, MO) or
vehicle control (water) by gavage every 12 h from 5 to 12 weeks of
age. Systolic BP was determined at 11.5 weeks by tail-cuff using a
sphygmomanometer (BP-98A; Softron INC., Tokyo, Japan). Rats
were anesthetized at 12 weeks with sodium pentobarbital and both
kidneys were removed causing fatal exsanguination. Total body
weight and kidney weight were measured; the left kidney was
homogenized in lysis buffer for protein extraction, and the right
kidney was immersed in 4% paraformaldehyde, embedded in
paraffin, and sectioned for immunohistochemistry. The protocol for
the use of these animals was approved by the Animal Care and Use
Committee at Fujita Health University.
Western blot analysis
Kidney lysates were prepared for immunoblot as described
previously.24,46 Contents of lysis buffer were 20 mM Tris (pH 7.4),
137 mM NaCl, 25 mM b-glycerophosphate, 2 mM EDTA, 1 mM
sodium orthovanadate, 2 mM dithiothreitol, 1 mM phenylmethyl-
sulfonyl fluoride, 5 mg ml1 aprotinin, and 5 mg ml1 leupeptin with
1% Triton X-100. Proteins (20 mg protein per lane) were separated
by 10% sodium dodecyl sulfate-polyacrylamide gel electrophoresis
and transferred to nitrocellulose membranes. Membranes were
blocked with 5% milk in TBS-T (20 mM Tris–HCl, pH 8.0, 137 mM
NaCl, and 0.05% Tween 20) for 1 h at room temperature and then
incubated overnight at 41C in primary antibody diluted at
1:2000–5000 in 5% milk–TBS-T. Membranes were then washed
three times with TBS-T and incubated with secondary antibody
conjugated to horseradish peroxidase diluted 1:2000–5000 in 5%
milk in TBS-T. Specific antibody signals were detected using an
enhanced chemiluminescence system (ECL Advance Western
Blotting Detection System; Amersham Life Sciences, Arlington
Heights, IL, USA). Images of the blots were captured, and the
intensity of the protein bands was quantified using a CS Analyzer 2.0
with a CCD camera (ATTO Corporation, Tokyo, Japan). Relative
band intensity was compared to gender-matched þ /þ kidneys
gavaged with control solution (set to 1.0).
Immunohistochemistry
Paraffin sections were heated to 1001C for 15 min in 10 mM sodium
citrate buffer (pH 6.0) to unmask antigens. Endogenous peroxidase
was destroyed by incubating sections in 0.3% H2O2/methanol, and
the sections were incubated with primary antibody (1:3000) for
PCNA overnight at 41C. Sections were incubated with biotinylated
anti-mouse secondary antibody and then with streptavidin con-
jugated to peroxidase (Histofine; Nichirei Biosciences, Tokyo,
Japan). Immune reaction products were developed using 3,30-
diaminobenzidine. Cystic surface area was measured from 10
random fields ( 100 magnification) of hematoxylin and eosin-
stained sections of renal cortex (N¼ 3). Cyst area (% of total field)
was measured by a naive observer using LUZEX FS software (Kideko
CO. LTD, Tokyo, Japan). ApopTag Peroxidase In situ Apoptosis
Detection Kit (Chemicon International, Temecula, CA, USA) was
used to detect apoptotic cells. PCNA-positive cells were counted
from 900 to 1400 cells per thin section and apoptotic cells from
approximately 700 cells per section from cortex of Cy/þ or þ /þ
rat kidneys ( 400 magnification).
Antibodies
Primary antibodies to ERK1,2 (K-23, SC-94), P-ERK (E-4, SC-7383),
and B-Raf (F-7, SC-5284) were obtained from Santa Cruz
Technology (Santa Cruz, CA, USA), and P-BRaf (no. 2696, Ser445)
was purchased from Cell Signaling Technology (Danvers, MA, USA).
Secondary antibodies conjugated to horseradish peroxidase were
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goat anti-rabbit IgG (SC-2054) and rabbit anti-mouse IgG (SC-
2055) from Santa Cruz Technology. Primary antibodies to PCNA
(P8825; Sigma Chemical) were used for immunohistochemistry.
Secondary antibodies, conjugated to biotin, were goat rabbit anti-
mouse IgGþ IgAþ IgM (HISTOFINE 426032) obtained from
Biosciences.
Measurement of SUN and urinary cAMP levels
SUN determinations were performed using a colorimetric assay
using a urease–indophenol method (Wako Pure Chemical Industries
Ltd, Osaka, Japan).46 To measure urinary cAMP levels, male Cy/þ
and Sprague–Dawley rats (n¼ 2 per group) were given free access to
food and water in metabolic cages, and urine was collected for a 24 h
period. cAMP levels were analyzed using a cAMP radioimmuno-
assay kit (Yamasa, Chiba, Japan).
Statistics
Data are represented as mean7s.e. Statistical significance was
determined by one-way analysis of variance and Student–Newman–-
Keuls post-test for multiple comparisons or unpaired t-test for
comparison between control and treated animals (Instat; Graphpad
Software Inc., San Diego, CA, USA).
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